NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · BBNX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Beta Bionics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Beta Bionics, Inc.’s next earnings report is currently expected on Feb 16, 2027, with estimated earnings per share of -$0.49. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Beta Bionics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 29, 2025 | -$0.39+23.53% vs estimate | $23.24M+6.1% vs estimate |
|---|
| Q1 2025 | May 6, 2025 | -$0.52-1.96% vs estimate | $17.64M+9.23% vs estimate |
|---|
| Q4 2024 | Mar 25, 2025 | -$1.82-333.33% vs estimate | $20.44M+1.22% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 9 contributors · Median target $25.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$39.14+$0.85 (+2.22%)
Novo Nordisk A/S’s quoted price sits in the lower half of its reported 52-week range, 39.0% below the high.
$79.93+$1.31 (+1.67%)
DexCom, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.67% below the high.
$152.50+$3.57 (+2.4%)
Insulet Corp.’s quoted price sits in the lower half of its reported 52-week range, 57.03% below the high.
$19.25+$0.04 (+0.21%)
MiniMed Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.2% below the high.
$19.79+$0.11 (+0.56%)
Tandem Diabetes Care, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.25% below the high.
$3.50+$0.07 (+2.04%)
MannKind Corporation’s quoted price sits in the lower half of its reported 52-week range, 46.24% below the high.
$4.23+$0.07 (+1.68%)
Oramed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.67% below the high.
